Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112492718> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3112492718 endingPage "ii178" @default.
- W3112492718 startingPage "ii178" @default.
- W3112492718 abstract "Abstract BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious consequence of cancer treatment that, for up to 30% of patients, persists beyond six months of completing chemotherapy. Scrambler therapy (ST) is a therapeutic modality with emerging evidence supporting its ability to diminish CIPN symptoms. METHODS Data was from a convenience sample of 24 CIPN patients (with symptoms between 1-240 months after platinum-based, taxane, or combination chemotherapy) completing 10 sessions of ST using the Calmare® device in the City of Hope Outpatient Physical Therapy Department. Patients were treated for ~45 minutes per session over 10 sessions. Patients received a standardized assessment pre- and post ST that included: EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20), mono-filament testing, pain intensity numerical rating scale, numbness scale, extensor hallicus longus strength, Timed Up and Go, Romberg, and single leg balance. RESULTS Regardless of length of symptoms, significant changes were seen in post-treatment assessment of quality of life as measured by the QLQ-CIPN-20 and numbness scale. Post-treatment QLQ-CIPN-20 total scores decreased by an average of 7.1 points (n= 24, p< .01). Numbness in the left lower extremity decreased by an average of 1 point of the 0-4 point scale (n=24, p=.0007) and 1.09 points on the right lower extremity (n=24, p < .0004). There was a trend towards improvements in pain, monofilament testing, single leg balance, and Romberg test, though they did not reach a level of significance. Surprisingly, only 3 of 24 patients reported pain related to their CIPN at the start of treatment. CONCLUSION For patients with CIPN, scrambler therapy improves numbness and improves quality of life measures. This suggests an important role for this treatment modality in cancer patients suffering from this debilitating condition." @default.
- W3112492718 created "2020-12-21" @default.
- W3112492718 creator A5007181999 @default.
- W3112492718 creator A5012957571 @default.
- W3112492718 creator A5072674557 @default.
- W3112492718 date "2020-11-01" @default.
- W3112492718 modified "2023-09-25" @default.
- W3112492718 title "QOLP-16. EFFICACY OF SCRAMBLER THERAPY (CALMARE®) FOR THE TREATMENT OF CHRONIC CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY" @default.
- W3112492718 doi "https://doi.org/10.1093/neuonc/noaa215.741" @default.
- W3112492718 hasPublicationYear "2020" @default.
- W3112492718 type Work @default.
- W3112492718 sameAs 3112492718 @default.
- W3112492718 citedByCount "0" @default.
- W3112492718 crossrefType "journal-article" @default.
- W3112492718 hasAuthorship W3112492718A5007181999 @default.
- W3112492718 hasAuthorship W3112492718A5012957571 @default.
- W3112492718 hasAuthorship W3112492718A5072674557 @default.
- W3112492718 hasBestOaLocation W31124927181 @default.
- W3112492718 hasConcept C126322002 @default.
- W3112492718 hasConcept C134018914 @default.
- W3112492718 hasConcept C138496976 @default.
- W3112492718 hasConcept C15744967 @default.
- W3112492718 hasConcept C159110408 @default.
- W3112492718 hasConcept C168031717 @default.
- W3112492718 hasConcept C1862650 @default.
- W3112492718 hasConcept C2776694085 @default.
- W3112492718 hasConcept C2779289229 @default.
- W3112492718 hasConcept C2779901536 @default.
- W3112492718 hasConcept C2779951463 @default.
- W3112492718 hasConcept C46762472 @default.
- W3112492718 hasConcept C555293320 @default.
- W3112492718 hasConcept C71924100 @default.
- W3112492718 hasConcept C83849319 @default.
- W3112492718 hasConcept C99508421 @default.
- W3112492718 hasConceptScore W3112492718C126322002 @default.
- W3112492718 hasConceptScore W3112492718C134018914 @default.
- W3112492718 hasConceptScore W3112492718C138496976 @default.
- W3112492718 hasConceptScore W3112492718C15744967 @default.
- W3112492718 hasConceptScore W3112492718C159110408 @default.
- W3112492718 hasConceptScore W3112492718C168031717 @default.
- W3112492718 hasConceptScore W3112492718C1862650 @default.
- W3112492718 hasConceptScore W3112492718C2776694085 @default.
- W3112492718 hasConceptScore W3112492718C2779289229 @default.
- W3112492718 hasConceptScore W3112492718C2779901536 @default.
- W3112492718 hasConceptScore W3112492718C2779951463 @default.
- W3112492718 hasConceptScore W3112492718C46762472 @default.
- W3112492718 hasConceptScore W3112492718C555293320 @default.
- W3112492718 hasConceptScore W3112492718C71924100 @default.
- W3112492718 hasConceptScore W3112492718C83849319 @default.
- W3112492718 hasConceptScore W3112492718C99508421 @default.
- W3112492718 hasIssue "Supplement_2" @default.
- W3112492718 hasLocation W31124927181 @default.
- W3112492718 hasLocation W31124927182 @default.
- W3112492718 hasLocation W31124927183 @default.
- W3112492718 hasOpenAccess W3112492718 @default.
- W3112492718 hasPrimaryLocation W31124927181 @default.
- W3112492718 hasRelatedWork W2394330061 @default.
- W3112492718 hasRelatedWork W2944676959 @default.
- W3112492718 hasRelatedWork W2945532734 @default.
- W3112492718 hasRelatedWork W4241159579 @default.
- W3112492718 hasRelatedWork W4251922279 @default.
- W3112492718 hasRelatedWork W4252521261 @default.
- W3112492718 hasRelatedWork W4254033585 @default.
- W3112492718 hasRelatedWork W4293570334 @default.
- W3112492718 hasRelatedWork W4295779519 @default.
- W3112492718 hasRelatedWork W4312210684 @default.
- W3112492718 hasVolume "22" @default.
- W3112492718 isParatext "false" @default.
- W3112492718 isRetracted "false" @default.
- W3112492718 magId "3112492718" @default.
- W3112492718 workType "article" @default.